Chemclin Diagnostics(SH:688468)2025-02-27 08:20Financial Performance - Total revenue for 2024 was RMB 43,628.98 million, a decrease of 2.03% compared to the previous year[5] - Operating profit for 2024 was RMB 13,475.09 million, down 18.96% year-over-year[5] - Net profit attributable to shareholders was RMB 12,699.28 million, reflecting a decline of 13.83% from the prior year[5] - Basic earnings per share decreased to RMB 0.32, a drop of 13.51% compared to the previous year[5] - The weighted average return on equity decreased to 9.17%, down 1.56 percentage points from the previous year[3] Assets and Operations - Total assets at the end of the reporting period were RMB 183,216.71 million, an increase of 0.64% from the beginning of the year[5] - The company launched the fully automated immunoassay system LICA® AT 5000, which gained recognition from high-end hospital clients[6] - The company’s R&D and production base in Suzhou has commenced operations, enhancing long-term growth potential[6] Strategic Focus - The company is focusing on precision medicine for diseases such as thyroid, reproductive assistance, cardiovascular, and central nervous system disorders[6] - The company is committed to a "dual-drive" strategy leveraging its leading LICA® technology platform for strong import substitution[6]